Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

Daria Podlekareva(University of Copenhagen), Daniel Grint(London School of Hygiene & Tropical Medicine), Ole Kirk(University of Copenhagen), Amanda Mocroft(University of Copenhagen), Jens Lundgren(Centre of Excellence for Health, Immunity and Infections), Igor Karpov, M. Losso(Hospital Ramos Mejía), N. Chentsova(Kyiv City Clinical Oncology Center), Indra Zeltiņa(University of Copenhagen), K. Mansinho(Hospital de Egas Moniz), Miłosz Parczewski(Pomeranian Medical University), Aza Rakmanova(Botkin Hospital)
HIV Medicine
May 18, 2015
10.1111/hiv.12254
Cited by 11

Related Papers

Industrial enzyme applications
|Current Opinion in Biotechnology|2002|1.5k
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987